This study reported outcomes of 14 patients with recurrent, radioactive iodine (RAI) refractory differentiated thyroid cancer (DTC) treated with IMPT. At 8 months, all patients were alive without local-regional failure.
Acute grade 3 toxicities were limited to 1 patient with dysphagia, requiring feeding tube placement. Two patients experienced late grade 3 esophageal stenosis requiring dilation. There were no grade 4 or 5 toxicities. The authors suggested that IMPT is a promising treatment for this patient population.